E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic cancer of the colon or rectum. |
Cáncer metastásico de colon o recto. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety profile of bevacizumab when combined with fluoropyrimidine-based chemotherapy regimens as first line treatment of metastatic cancer of the colon or rectum. |
Evaluar el perfil de seguridad de Bevacizumab cuando se combina con regímenes de quimioterapia basada en fluoropirimidina como primera línea de tratamiento del cáncer metastásico de colon o recto. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effectiveness of bevacizumab as measured by time to disease progression and duration of survival. |
Estudiar la eficacia de Bevacizumab evaluada como el tiempo hasta la progresión de la enfermedad y el tiempo de supervivencia. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with histologically confirmed diagnosis of metastatic CRC, untreated yet with chemotherapy for metastatic disease (prior adjuvant chemotherapy for colorectal cancer allowed), who are scheduled to start first line fluoropyrimidine-based chemotherapeutic treatment. 2. Age ? 18. 3. Measurable or non-measurable disease. 4. Performance status ECOG performance status 0 or 1. 5. Life expectancy greater than 3 months. 6. Neutrophils ? 1?500/µl, Platelets ? 100?000/µl, AST/ALT ? 2.5 × ULN (< 5 × ULN if liver metastases), Alkaline phosphatase ? 2.5 × ULN, Serum bilirubin ? 1.5 × ULN, Serum Creatinine ? 1.5 × ULN. Urine dipstick of proteinuria <2+. Patients discovered to have equal to or greater than 2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate equal to or less than 1 g of protein/24 hr. 7. Women of childbearing potential must have a negative serum pregnancy test done 1 week prior to the administration of the study drug. She and her partner should prevent pregnancy (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) up to at least 6 months after last treatment completion or the last drug dose, whatever happens first. 8. Signed written informed consent according to ICH/GCP and the local regulations (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) will be obtained prior to any study specific screening procedures. 9. Patient must be able to comply with the protocol |
|
E.4 | Principal exclusion criteria |
1. Treatment with first-line chemotherapy for metastatic CRC. 2. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 0 (Patients must have recovered from any major surgery), or anticipation of need for major surgical procedure during the course of the study. 3. Planned radiotherapy for underlying disease (prior completed radiotherapy treatment allowed). 4. Clinical or radiological evidence of CNS metastases. 5. Past or current history (within the last 5 years) of malignancies except for the indication under this study and curatively treated: - Basal and squamous cell carcinoma of the skin - In-situ carcinoma of the cervix 6. Serious non-healing wound or ulcer. 7. Evidence of bleeding diathesis or coagulopathy. 8. Uncontrolled hypertension. 9. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (? 6 months), myocardial infarction (? 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. 10. Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes i.e. except for anticoagulation for maintenance of patency of permanent indwelling IV catheters. 11. Treatment with any investigational drug (including IMMP, EGFR inhibitors, COX-2 inhibitors) or participation in another investigational study within 30 days prior to enrolment. 12. Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications 13. Ongoing treatment with aspirin (> 325 mg/day) or other medications known to predispose to gastrointestinal ulceration 14. Pregnancy (positive serum pregnancy test) and lactation 15. Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Main parameters of safety: The incidence of serious adverse events related to bevacizumab and the incidence of specific adverse events (serious and non-serious) such as gastro-intestinal perforation, wound healing complication, bleeding, hypertension and proteinuria will be investigated. NCI-CTCAE criteria (version 3.0) will be used.
Main parameters of efficacy: Duration of survival (defined as the time period from the start of first line therapy to death) and time to disease progression (defined as the time period from the start of first line therapy to investigator assessed disease progression) at the end of study. |
Principales parámetros de seguridad: Se investigará la incidencia de acontecimientos adversos graves relacionados con Bevacizumab y la incidencia de acontecimientos adversos específicos (graves y no graves) como la perforación gastrointestinal, complicaciones en la cicatrización de las heridas, sangrado, hipertensión y proteinuria. Se utilizarán los criterios NCI-CTCAE (versión 3.0).
Principales parámetros de eficacia: Duración de la supervivencia (definida como el periodo de tiempo desde el inicio de la primera línea de tratamiento hasta el fallecimiento). Tiempo hasta la progresión de la enfermedad (definido como el periodo de tiempo desde el inicio de la primera línea de tratamiento hasta la evaluación del investigador de la progresión de la enfermedad). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 39 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 295 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Algeria |
Argentina |
Australia |
Austria |
Bangladesh |
Belgium |
Brazil |
Bulgaria |
Canada |
Colombia |
Ecuador |
Egypt |
Finland |
Germany |
Greece |
Hungary |
India |
Ireland |
Israel |
Italy |
Kuwait |
Lebanon |
Lithuania |
Mexico |
Morocco |
Netherlands |
Norway |
Poland |
Portugal |
Romania |
Russian Federation |
Saudi Arabia |
Slovakia |
Slovenia |
Spain |
Sweden |
Switzerland |
Turkey |
United Kingdom |
Uruguay |
Venezuela, Bolivarian Republic of |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patient recruitment finished in the beginning of March 2006 and as per protocol, the minimal treatment duration is 6 months (see Section 3.) and the median treatment duration per patient is expected to be 10 months (see Section 8.3.4.) Therefore the study will end on July 31st 2007 (which is more than 2 years after the median patient recruitment) and it is expected that by that time, the number of patients still under study treatment will be very low |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |